Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 14/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.38 |
| ▸ | USP2 | O75604 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24960890 | 1.00 | CYP2D6 (0.41) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1PIK3CD | |
| SCHEMBL21290867 | 1.00 | CYP2D6 (0.41) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1PIK3CD | |
| SCHEMBL3421093 | 0.88 | CYP3A4 (0.42) | CYP2D6CYP3A4ALDH1A1PIK3CDCYP1A2 | |
| SCHEMBL12848310 | 0.87 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1PIK3CD | |
| SCHEMBL23122665 | 0.84 | HRH2 (0.33) | CYP2D6CYP3A4HRH2HRH1HRH3 | |
| SCHEMBL16849184 | 0.82 | PIK3CD (0.39) | CYP2D6SMN1; SMN2PIK3CDCYP1A2USP2 | |
| SCHEMBL3419547 | 0.80 | CYP2D6 (0.42) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1PIK3CD | |
| SCHEMBL23374702 | 0.78 | CYP2D6 (0.43) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1PIK3CD | |
| SCHEMBL24235277 | 0.78 | CYP2D6 (0.51) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1PIK3CD | |
| SCHEMBL22308322 | 0.76 | CYP2D6 (0.39) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023006019-A1 | POLYSUBSTITUTED BENZENE PD-L1 INHIBITOR, COMPOSITION AND USE THEREOF | 杭州和正医药有限公司 | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CYP2D6 1710/4885SMN1; SMN2 3055/4885CYP3A4 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.